PTK7 helps detect T lymphoblastic leukemia/lymphoma by flow cytometry

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) is a cancer of immature T cells.
• Flow cytometry identifies T-ALL by detecting aberrant antigen expression.
• A reliable marker for T-ALL diagnosis and monitoring is needed.

Purpose of the Study:

• To evaluate the utility of protein tyrosine kinase-7 (PTK7) in T-ALL diagnosis, minimal/measurable residual disease (MRD) detection, and relapse monitoring.
• To assess PTK7 expression in T-ALL patient samples using flow cytometry.

Main Methods:

• Retrospective analysis of flow cytometry data from 175 T-ALL patients.
• Evaluation of PTK7 expression at initial diagnosis, MRD, and relapse.
• Comparison of PTK7 expression levels in T-ALL cases versus mature T cells.

Main Results:

• PTK7 was positive in 87.76% of T-ALL cases at diagnosis, 75% at MRD, and 100% at relapse.
• PTK7 expression remained consistent in CD34/TdT negative T-ALL.
• PTK7 expression showed a decrease at MRD but remained intact at relapse.

Conclusions:

• PTK7 is a highly effective marker for T-ALL diagnosis and MRD detection.
• PTK7 should be incorporated into flow cytometry panels for T-ALL evaluation.
• PTK7 aids in monitoring disease status from diagnosis through relapse.